Gonen Ashkensy

Title: Gonen Ashkensy: Innovator in Vascular Delivery Systems

Introduction

Gonen Ashkensy is a notable inventor based in Omer, Israel. He has made significant contributions to the field of drug delivery systems, particularly in targeting anti-cancer therapies. His innovative approach focuses on enhancing the effectiveness of chemotherapy through advanced targeting strategies.

Latest Patents

Gonen Ashkensy holds a patent for a vascular delivery system. This invention leverages the site-specific expression of selectins on endothelial cells during angiogenesis to target anti-cancer drugs effectively. The patent describes a novel drug targeting strategy that utilizes polymer-drug conjugates modified with carbohydrate ligands for vascular selectins. A model chemotherapeutic drug, doxorubicin, is conjugated with the E-selectin ligand, sLex, and attached to a biocompatible polymer known as HPMA. The research investigates the selective binding, cellular uptake, intracellular fate, and cytotoxicity of the polymer-bound drug in human endothelial cells.

Career Highlights

Gonen Ashkensy is affiliated with the Ben-Gurion University of the Negev Research and Development Authority. His work at this institution has allowed him to explore innovative solutions in the field of drug delivery, contributing to advancements in cancer treatment.

Collaborations

Gonen collaborates with esteemed colleagues, including Ayelet David and Yosi Shamay. Their combined expertise enhances the research and development of effective drug delivery systems.

Conclusion

Gonen Ashkensy is a pioneering inventor whose work in vascular delivery systems represents a significant advancement in targeted cancer therapies. His innovative strategies have the potential to improve the efficacy of chemotherapy, ultimately benefiting patients in need of effective treatment options.